注册 English

Development of LC-MS method for analysis of paclitaxel-inhibited growth and enhanced therapeutic response in human glioblastoma cells

Cai-Hou Lin ,  Xue-Xia Lin ,  Ling Lin ,  Jun-Ming Wang ,  Zhi-Xiong Lin ,  Jin-Ming Lin

downloadPDF
Citation:  Cai-Hou Lin, Xue-Xia Lin, Ling Lin, Jun-Ming Wang, Zhi-Xiong Lin, Jin-Ming Lin. Development of LC-MS method for analysis of paclitaxel-inhibited growth and enhanced therapeutic response in human glioblastoma cells[J]. Chinese Chemical Letters, 2015, 26(10): 1225-1230. doi: 10.1016/j.cclet.2015.03.007 shu

Development of LC-MS method for analysis of paclitaxel-inhibited growth and enhanced therapeutic response in human glioblastoma cells

    • 通讯作者: Zhi-Xiong Lin,
    Jin-Ming Lin,
  • 基金项目:

    We thank Dr. Yan-Li Guo, Qian Yang (The Frontier Science Department of Shiseido China Co., Ltd.) (The Frontier Science Department of Shiseido China Co., Ltd.)

    Qiushui Chen (Department of Chemistry, Tsinghua University) for assistance with MS analysis. We also thank Jun Dong, Xinliang DAI of the neurosurgery department of The Second Affiliated Hospital of Soochow University for assistance with cell culture. The work was supported by National Nature Science Foundation of China (Nos. 214350002, 81373373)  (Department of Chemistry, Tsinghua University)

    Education Resources System (No. CERS-1-75). (No. CERS-1-75)

摘要: Glioma stem cells are considered responsible for drug resistance and glioma relapse resulting in poor prognosis in glioblastomamultiforme. SU3 glioma cell is a highly invasive glioma stemcell line from the patients with glioblastoma multifrome. It is of great significance to study the efficacy and molecular mechanism for anticancer drug effects on SU3 glioma cells. In this work, we develop a liquid chromatography-mass spectrometry (LC-MS) method for direct analysis of the role of drugs (paclitaxel) on SU3 glioma cells at themolecular level. Weuse the specific fluorescence dyes to evaluate cell viability, the levels of ROS and GSH when the cells were treated with drugs. In addition, the LC-MS platform was successfully employed to detect the amount of 6-O-methylguanine, demonstrating that it is effective to induce cell apoptosis and enhance the cytotoxic response of SU3 glioma cells. The analytical linear equals are Y=9.49×105X+2.42×104 for 6-O-methylguanine (R2=0.9998) and Y=4.72×104X+2.21×103(R2=0.9996) for 7-methylguanine. Thus, the combination of cell-specific fluorescence dyes and LC-MS method enables us to reveal the molecular mechanism of paclitaxel-inhibited growth and enhanced therapeutic response in the chemotherapy for glioma multiforme.

English

  • 

    1. [1] D.N. Louis, H. Ohgaki, O.D. Wiestler, et al., The 2007WHOclassification of tumours of the central nervous system, Acta Neuropathol. 114(2007) 97-109.[1] D.N. Louis, H. Ohgaki, O.D. Wiestler, et al., The 2007WHOclassification of tumours of the central nervous system, Acta Neuropathol. 114(2007) 97-109.

    2. [2] B. Auffinger, A.L. Tobias, Y. Han, et al., Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy, Cell Death Differ. 21(2014) 1119-1131.[2] B. Auffinger, A.L. Tobias, Y. Han, et al., Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy, Cell Death Differ. 21(2014) 1119-1131.

    3. [3] E.K. Nduom, C.G. Hadjipanayis, E.G. Van Meir, Glioblastoma cancer stem-like cells:implications for pathogenesis and treatment, Cancer J. 18(2012) 100-106.[3] E.K. Nduom, C.G. Hadjipanayis, E.G. Van Meir, Glioblastoma cancer stem-like cells:implications for pathogenesis and treatment, Cancer J. 18(2012) 100-106.

    4. [4] S.D. Bao, Q.L. Wu, R.E. McLendon, et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature 444(2006) 756-760.[4] S.D. Bao, Q.L. Wu, R.E. McLendon, et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature 444(2006) 756-760.

    5. [5] J. Chen, Y.J. Li, T.S. Yu, et al., A restricted cell population propagates glioblastoma growth after chemotherapy, Nature 488(2012) 522-526.[5] J. Chen, Y.J. Li, T.S. Yu, et al., A restricted cell population propagates glioblastoma growth after chemotherapy, Nature 488(2012) 522-526.

    6. [6] D. Beier, J.B. Schulz, C.P. Beier, Chemoresistance of glioblastoma cancer stem cells-much more complex than expected, Mol. Cancer 10(2011) 128.[6] D. Beier, J.B. Schulz, C.P. Beier, Chemoresistance of glioblastoma cancer stem cells-much more complex than expected, Mol. Cancer 10(2011) 128.

    7. [7] Y. Wan, X.F. Fei, Z.M. Wang, et al., Expression of miR-125b in the new, highly invasive glioma stem cell and progenitor cell line SU3, Chin. J. Cancer 31(2012) 207-214.[7] Y. Wan, X.F. Fei, Z.M. Wang, et al., Expression of miR-125b in the new, highly invasive glioma stem cell and progenitor cell line SU3, Chin. J. Cancer 31(2012) 207-214.

    8. [8] S.M. Chang, P. Theodosopoulos, K. Lamborn, et al., Temozolomide in the treatment of recurrent malignant glioma, Cancer 100(2004) 605-611.[8] S.M. Chang, P. Theodosopoulos, K. Lamborn, et al., Temozolomide in the treatment of recurrent malignant glioma, Cancer 100(2004) 605-611.

    9. [9] D.T.M. Chan, W.S. Poon, Y.L. Chan, H.K. Ng, Temozolomide in the treatment of recurrent malignant glioma in Chinese patients, Hong Kong Med. J. 11(2005) 452-456.[9] D.T.M. Chan, W.S. Poon, Y.L. Chan, H.K. Ng, Temozolomide in the treatment of recurrent malignant glioma in Chinese patients, Hong Kong Med. J. 11(2005) 452-456.

    10. [10] H.S. Friedman, T. Kerby, H. Calvert, Temozolomide and treatment of malignant glioma, Clin. Cancer Res. 6(2000) 2585-2597.[10] H.S. Friedman, T. Kerby, H. Calvert, Temozolomide and treatment of malignant glioma, Clin. Cancer Res. 6(2000) 2585-2597.

    11. [11] M. Lacroix, D. Abi-Said, D.R. Fourney, et al., A multivariate analysis of 416 patients with glioblastoma multiforme:prognosis, extent of resection, and survival, J. Neurosurg. 95(2001) 190-198.[11] M. Lacroix, D. Abi-Said, D.R. Fourney, et al., A multivariate analysis of 416 patients with glioblastoma multiforme:prognosis, extent of resection, and survival, J. Neurosurg. 95(2001) 190-198.

    12. [12] X.Y. Ma, Y.F. Lv, J. Liu, et al., Survival analysis of 205 patients with glioblastoma multiforme:clinical characteristics, treatment and prognosis in China, J. Clin. Neurosci. 16(2009) 1595-1598.[12] X.Y. Ma, Y.F. Lv, J. Liu, et al., Survival analysis of 205 patients with glioblastoma multiforme:clinical characteristics, treatment and prognosis in China, J. Clin. Neurosci. 16(2009) 1595-1598.

    13. [13] J.-F. Mineo, A. Bordron, M. Baroncini, et al., Prognosis factors of survival time in patients with glioblastoma multiforme:a multivariate analysis of 340 patients, Acta Neurochir. 149(2007) 245-253.[13] J.-F. Mineo, A. Bordron, M. Baroncini, et al., Prognosis factors of survival time in patients with glioblastoma multiforme:a multivariate analysis of 340 patients, Acta Neurochir. 149(2007) 245-253.

    14. [14] Z.N. Demidenko, S. Kalurupalle, C. Hanko, et al.,Mechanism of G1-like arrest by low concentrations of paclitaxel:next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis, Oncogene 27(2008) 4402-4410.[14] Z.N. Demidenko, S. Kalurupalle, C. Hanko, et al.,Mechanism of G1-like arrest by low concentrations of paclitaxel:next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis, Oncogene 27(2008) 4402-4410.

    15. [15] A. Thakur, N. Joshi, T. Shanmugam, R. Banerjee, Proapoptotic miltefosine nanovesicles show synergism with paclitaxel:implications for glioblastoma multiforme therapy, Cancer Lett. 334(2013) 274-283.[15] A. Thakur, N. Joshi, T. Shanmugam, R. Banerjee, Proapoptotic miltefosine nanovesicles show synergism with paclitaxel:implications for glioblastoma multiforme therapy, Cancer Lett. 334(2013) 274-283.

    16. [16] S. Jeyapalan, J. Boxerman, J. Donahue, et al., Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma:a Brown University Oncology Group Study, Am. J. Clin. Oncol. 37(2014) 444-449.[16] S. Jeyapalan, J. Boxerman, J. Donahue, et al., Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma:a Brown University Oncology Group Study, Am. J. Clin. Oncol. 37(2014) 444-449.

    17. [17] J.A. Sparano, M.L. Wang, S. Martino, et al., Weekly paclitaxel in the adjuvant treatment of breast cancer, N. Engl. J. Med. 358(2008) 1663-1671.[17] J.A. Sparano, M.L. Wang, S. Martino, et al., Weekly paclitaxel in the adjuvant treatment of breast cancer, N. Engl. J. Med. 358(2008) 1663-1671.

    18. [18] S. Kumar, H. Mahdi, C. Bryant, et al., Clinical trials and progress with paclitaxel in ovarian cancer, Int. J. Women's Health 2(2010) 411-427.[18] S. Kumar, H. Mahdi, C. Bryant, et al., Clinical trials and progress with paclitaxel in ovarian cancer, Int. J. Women's Health 2(2010) 411-427.

    19. [19] G.R. Blumenschein Jr., F. Kabbinavar, H. Menon, et al., A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer, Ann. Oncol. 22(2011) 2057-2067.[19] G.R. Blumenschein Jr., F. Kabbinavar, H. Menon, et al., A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer, Ann. Oncol. 22(2011) 2057-2067.

    20. [20] H.H. Wilke, K. Muro, E. Van Cutsem, et al., Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW):a doubleblind, randomised phase 3 trial, Lancet Oncol. 15(2014) 1224-1235.[20] H.H. Wilke, K. Muro, E. Van Cutsem, et al., Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW):a doubleblind, randomised phase 3 trial, Lancet Oncol. 15(2014) 1224-1235.

    21. [21] A.E. Sosa, J.J. Grau, L. Feliz, et al., Outcome of patients treated with palliative weekly paclitaxel plus cetuximab in recurrent head and neck cancer after failure of platinum-based therapy, Eur. Arch. Otorhinolaryngol. 271(2014) 373-378.[21] A.E. Sosa, J.J. Grau, L. Feliz, et al., Outcome of patients treated with palliative weekly paclitaxel plus cetuximab in recurrent head and neck cancer after failure of platinum-based therapy, Eur. Arch. Otorhinolaryngol. 271(2014) 373-378.

    22. [22] J.J. Grau, M. Caballero, E. Verger, M. Monzo, J. Blanch, Weekly paclitaxel for platinresistant stage IV head and neck cancer patients, Acta Otolaryngol. 129(2009) 1294-1299.[22] J.J. Grau, M. Caballero, E. Verger, M. Monzo, J. Blanch, Weekly paclitaxel for platinresistant stage IV head and neck cancer patients, Acta Otolaryngol. 129(2009) 1294-1299.

    23. [23] S.H. Tseng, M.S. Bobola, M.S. Berger, J.R. Silber, Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines, Neuro Oncol. 1(1999) 101-108.[23] S.H. Tseng, M.S. Bobola, M.S. Berger, J.R. Silber, Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines, Neuro Oncol. 1(1999) 101-108.

    24. [24] A. Goel, B.B. Aggarwal, Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs, Nutr. Cancer 62(2010) 919-930.[24] A. Goel, B.B. Aggarwal, Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs, Nutr. Cancer 62(2010) 919-930.

    25. [25] A.R. Dehdashti, M.E. Hegi, L. Regli, A. Pica, R. Stupp, New trends in the medical management of glioblastoma multiforme:the role of temozolomide chemotherapy, Neurosurg. Focus 20(2006) E6.[25] A.R. Dehdashti, M.E. Hegi, L. Regli, A. Pica, R. Stupp, New trends in the medical management of glioblastoma multiforme:the role of temozolomide chemotherapy, Neurosurg. Focus 20(2006) E6.

    26. [26] J.L. Villano, T.E. Seery, L.R. Bressler, Temozolomide in malignant gliomas:current use and future targets, Cancer Chemother. Pharmacol. 64(2009) 647-655.[26] J.L. Villano, T.E. Seery, L.R. Bressler, Temozolomide in malignant gliomas:current use and future targets, Cancer Chemother. Pharmacol. 64(2009) 647-655.

    27. [27] M.-S. Tang, J.B. Zheng, M.F. Denissenko, G.P. Pfeifer, Y. Zheng, Use of UvrABC nuclease to quantify benzo[a]pyrene diol epoxide-DNA adduct formation at methylated versus unmethylated CpG sites in the p53 gene, Carcinogenesis 20(1999) 1085-1089.[27] M.-S. Tang, J.B. Zheng, M.F. Denissenko, G.P. Pfeifer, Y. Zheng, Use of UvrABC nuclease to quantify benzo[a]pyrene diol epoxide-DNA adduct formation at methylated versus unmethylated CpG sites in the p53 gene, Carcinogenesis 20(1999) 1085-1089.

    28. [28] Q.S. Chen, J. Wu, Y.D. Zhang, J.M. Lin, Qualitative and quantitative analysis of tumor cell metabolism via stable isotope labeling assisted microfluidic chip electrospray ionization mass spectrometry, Anal. Chem. 84(2012) 1695-1701.[28] Q.S. Chen, J. Wu, Y.D. Zhang, J.M. Lin, Qualitative and quantitative analysis of tumor cell metabolism via stable isotope labeling assisted microfluidic chip electrospray ionization mass spectrometry, Anal. Chem. 84(2012) 1695-1701.

    29. [29] J. Zhang, J. Wu, H.F. Li, Q.S. Chen, J.M. Lin, An in vitro liver model on microfluidic device for analysis of capecitabine metabolite using mass spectrometer as detector, Biosens. Bioelectron. 68(2015) 322-328.[29] J. Zhang, J. Wu, H.F. Li, Q.S. Chen, J.M. Lin, An in vitro liver model on microfluidic device for analysis of capecitabine metabolite using mass spectrometer as detector, Biosens. Bioelectron. 68(2015) 322-328.

    30. [30] J. Wu, Q.S. Chen, W. Liu, J.M. Lin, A simple and versatile microfluidic cell density gradient generator for quantum dot cytotoxicity assay, Lab Chip 13(2013) 1948-1954.[30] J. Wu, Q.S. Chen, W. Liu, J.M. Lin, A simple and versatile microfluidic cell density gradient generator for quantum dot cytotoxicity assay, Lab Chip 13(2013) 1948-1954.

    31. [31] R.Z. Ning, S.Q. Wang, J. Wu, F. Wang, J.M. Lin, ZnO nanowire arrays exhibit cytotoxic distinction to cancer cells with different surface charge density:cytotoxicity is charge-dependent, Small 10(2014) 4113-4117.[31] R.Z. Ning, S.Q. Wang, J. Wu, F. Wang, J.M. Lin, ZnO nanowire arrays exhibit cytotoxic distinction to cancer cells with different surface charge density:cytotoxicity is charge-dependent, Small 10(2014) 4113-4117.

    32. [32] M.A. Kang, E.-Y. So, A.L. Simons, D.R. Spitz, T. Ouchi, DNA damage induces reactive oxygen species generation through the H2AX-Nox1/Rac1 pathway, Cell Death Dis. 3(2012) e249.[32] M.A. Kang, E.-Y. So, A.L. Simons, D.R. Spitz, T. Ouchi, DNA damage induces reactive oxygen species generation through the H2AX-Nox1/Rac1 pathway, Cell Death Dis. 3(2012) e249.

    33. [33] A.A. Alfadda, R.M. Sallam, Reactive oxygen species in health and disease, J. Biomed. Biotechnol. 2012(2012) 936486.[33] A.A. Alfadda, R.M. Sallam, Reactive oxygen species in health and disease, J. Biomed. Biotechnol. 2012(2012) 936486.

    34. [34] T. Finkel, Signal transduction by reactive oxygen species, J. Cell Biol. 194(2011) 7-15.[34] T. Finkel, Signal transduction by reactive oxygen species, J. Cell Biol. 194(2011) 7-15.

    35. [35] E. Laborde, Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death, Cell Death Differ. 17(2010) 1373-1380.[35] E. Laborde, Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death, Cell Death Differ. 17(2010) 1373-1380.

    36. [36] M.L. Circu, T.Y. Aw, Glutathione and modulation of cell apoptosis, BBA-Mol. Cell Res. 1823(2012) 1767-1777.[36] M.L. Circu, T.Y. Aw, Glutathione and modulation of cell apoptosis, BBA-Mol. Cell Res. 1823(2012) 1767-1777.

    37. [37] K. Aquilano, S. Baldelli, M.R. Ciriolo, Glutathione:new roles in redox signaling for an old antioxidant, Front. Pharmacol. 5(2014) 196.[37] K. Aquilano, S. Baldelli, M.R. Ciriolo, Glutathione:new roles in redox signaling for an old antioxidant, Front. Pharmacol. 5(2014) 196.

    38. [38] M.J. Morgan, Z.G. Liu, Crosstalk of reactive oxygen species and NF-kB signaling, Cell Res. 21(2011) 103-115.[38] M.J. Morgan, Z.G. Liu, Crosstalk of reactive oxygen species and NF-kB signaling, Cell Res. 21(2011) 103-115.

    39. [39] T. Hagen, Oxygen versus reactive oxygen in the regulation of HIF-1a:the balance tips, Biochem. Res. Int. 2012(2012) 436981.[39] T. Hagen, Oxygen versus reactive oxygen in the regulation of HIF-1a:the balance tips, Biochem. Res. Int. 2012(2012) 436981.

    40. [40] T. Maraldi, C. Prata, C. Caliceti, et al., VEGF-induced ROS generation from NAD(P)H oxidases protects human leukemic cells from apoptosis, Int. J. Oncol. 36(2010) 1581-1589.[40] T. Maraldi, C. Prata, C. Caliceti, et al., VEGF-induced ROS generation from NAD(P)H oxidases protects human leukemic cells from apoptosis, Int. J. Oncol. 36(2010) 1581-1589.

    41. [41] J. Chen, R.M. McKay, L.F. Parada, Malignant glioma:lessons from genomics, mouse models, and stem cells, Cell 149(2012) 36-47.[41] J. Chen, R.M. McKay, L.F. Parada, Malignant glioma:lessons from genomics, mouse models, and stem cells, Cell 149(2012) 36-47.

  • 加载中
WeChat 扫一扫看文章
计量
  • PDF下载量:  0
  • 文章访问数:  1114
  • HTML全文浏览量:  30
文章相关
  • 发布日期:  2015-03-10
  • 收稿日期:  2015-02-07
  • 网络出版日期:  2015-03-03
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

/

返回文章

All Rights Reserved by the Chinese Chemical Society   中国化学会 版权所有 京ICP备05002797号

本系统由北京仁和汇智信息技术有限公司开发    技术支持: info@rhhz.net